Navigation Links
DIFICID™ Demonstrated Early Superiority in the First 12 Days Compared to Vancomycin in New Analysis of Phase 3 Study Results
Date:10/20/2011

SAN DIEGO, Oct. 20, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today that data being presented at the 49th Annual Meeting of the Infectious Diseases Society of America (IDSA) demonstrate that patients treated with DIFICID™ (fidaxomicin) tablets for Clostridium difficile-associated diarrhea (CDAD) experienced faster resolution of diarrhea and lower risk of death during the first 12 days following initiation of treatment compared to patients treated with vancomycin. The retrospective analysis of results from two large, multi-national Phase 3 clinical studies, which assessed the efficacy of DIFICID versus vancomycin for the treatment of CDAD in adults, was completed by researchers from the National Institute for Health Research (NIHR) Biomedical Research Centre, Oxford,  a research partnership between the Oxford Radcliffe Hospitals and the University of Oxford.

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

In the analysis, patients treated with DIFICID experienced a 37% reduction in persistent diarrhea or death through day 12 of the study (95% CI: 2-60%; p=0.037) compared to those treated with vancomycin. These data are among those featured in a late-breaking poster presentation at the IDSA annual meeting being held in Boston from October 20-23.

"We were encouraged by the results of the Phase 3 clinical studies and believed that a more comprehensive look at the patient characteristics of the Phase 3 study participants might yield even greater insights into the use of DIFICID for the treatment of CDAD," said Sarah Walker, PhD, Senior Statistician at the NIHR Biomedical Research Centre, Oxford, and the primary author of the analysis. "In our analysis, we found that DIFICID not only reduced persistent diarrhea and early death
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Optimer Pharmaceuticals and Astellas Receive Positive Opinion from CHMP for European Approval of DIFICID™
2. Optimer to Provide DIFICID™ Launch Update at Morgan Stanley Global Healthcare Conference
3. Clinical Infectious Diseases Publishes Subgroup Analysis Showing Optimers DIFICID™ (fidaxomicin) Tablets Exhibited Higher Clinical Cure and Global Cure Rates Than Vancomycin in Patients with Clostridium difficile-Associated Diarrhea (CDAD) Receivin
4. Optimer Launches DIFICID™ (fidaxomicin) Tablets for Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) in Patients 18 Years of Age and Older
5. Data Presented at Digestive Disease Week Highlights Additional Analysis of DIFICID™ Phase 3 Data
6. Optimer Pharmaceuticals and Cubist Pharmaceuticals Announce Collaboration to Co-Promote DIFICID™ (Fidaxomicin) for Clostridium difficile Infection in the United States
7. Optimer Announces that the U.S. Food and Drug Administrations Anti-Infective Drugs Advisory Committee Voted Unanimously to Recommend Approval of Novel Antibiotic Dificid™ for Treatment of Patients with Clostridium difficile infection (CDI)
8. New Study Published in New England Journal of Medicine Shows Investigational BIBF 1120 Demonstrated Positive Trend in Reducing Lung Function Loss in Idiopathic Pulmonary Fibrosis
9. Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
10. Preclinical Studies in Pancreatic Cancer and Melanoma Demonstrated ADI-PEG 20 Works Synergistically With Inhibitors of Autophagy
11. Isis Pharmaceuticals Reports That Its Selective CRP Inhibitor Demonstrated Activity in a Phase 1 Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Celsion Corporation (the "Company") (NASDAQ: CLSN ) ... investors to purchase an aggregate of approximately $15 million ... direct offering, led by a dedicated health care fund. ... with these investors pursuant to which the Company agreed ...
(Date:1/15/2014)... BreedIT Corp (OTC: BRDT), through its ... highly sophisticated agro-breeding solutions for plant breeders and researchers, ... board of directors appointed chemistry and pharmaceutical industry expert ... of the board. From 1975 to 2012, ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
Breaking Medicine Technology:Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
... 11, 2011 Tonight,s "Dan Rather Reports" examines ... of antibiotics. Every year, more than 90,000 Americans ... antibiotic-resistant infections, caused directly by the overuse of ... $35 billion a year.  In tonight,s program, Dan ...
... 2011 WebMD Health Corp. (Nasdaq: WBMD ) ... million aggregate principal amount of 2.50% Convertible Notes due 2018 ... the exercise in full of the initial purchaser,s over-allotment option). ... to Rule 144A under the Securities Act of 1933.   ...
Cached Medicine Technology:Dan Rather Reports Investigates our Heavy Dependence on Antibiotics - What are the Causes... and the Consequences? 2Dan Rather Reports Investigates our Heavy Dependence on Antibiotics - What are the Causes... and the Consequences? 3Dan Rather Reports Investigates our Heavy Dependence on Antibiotics - What are the Causes... and the Consequences? 4WebMD Closes Offering of 2.50% Convertible Notes Due 2018 2
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... 2014U.S. military personnel who served in Iraq and ... brain injury (TBI) were compared to military personnel ... reasons. Differences in measures of overall disability, cognitive ... injury are reported in an article in ... Mary Ann Liebert, Inc., publishers. The article is ...
(Date:4/17/2014)... April 17, 2014-- Colic affects about one in five ... numerous pediatric visits during the first several months after ... symptoms was showing promise; however, the April 1, 2014 ... Sung, Valerie) reported on a study, "Probiotics and Infant ... L reuteri for infant colic did not ...
(Date:4/17/2014)... Calif.) An international team led by researchers at ... complex, which plays a key role in cell division, ... This is the first time the complex has been ... make cyclin B1/Cdk1 an excellent target to control cellular ... The research was published online today in the journal ...
(Date:4/17/2014)... not uncommon these days to find a colored ribbon representing ... breast cancer. But what color ribbon does one think of ... designated color, for many suffering from the disease, black may ... University study consisting of lung cancer patients, primarily smokers between ... more light on the stigma often felt by these patients, ...
Breaking Medicine News(10 mins):Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... have alerted the public about toxic carrot juice supplied ... Canadians// due to the contamination caused by the botulism ... by Bolthouse Farms, nearly 10 Toronto Businesses continued to ... States nearly four were hospitalized after consuming the juice, ...
... may be governed by her ovaries according to a new ... Claire// showed that women put more time and effort into ... a woman’s clothes and makeup affected at that time of ... men and each other alter as well. ,Study's ...
... dengue fever grips the country, another viral disease chikungunya ... //have been reported across nine states. ,Though Delhi ... worst hit is Karnataka with over 756,028 suspected cases ... ,Maharashtra has 262,595 suspected and 679 confirmed cases. ...
... indeed a wake-up call to the food and drug watchdog, ... in the market. This has been put forth vociferously by ... advisory panel. ,A report enabled by The Institute ... the FDA with more manpower, finance and authority to be ...
... For Health Technologies Inc., makers of IntelliFill i.v.?, ... IV medications in syringes//, announced today that Children’s ... producing over three million syringes using the IntelliFill ... October 2002. The hospital’s inpatient pharmacy is currently ...
... Dr Mukesh Haikerwal, said today the Government must make ... to be truly effective in meeting the needs of ... were announced today by the Prime Minister, and the ... care. ,While the AMA is generally pleased ...
Cached Medicine News:Health News:Women’s Fashion Sense Linked to Her Ovulatio 2Health News:Medical Center Tops 3 Million IV Syringes Using IntelliFill i.v. Robotics 2Health News:Mental Health Package Regrettably Undervalues the Role of the GP 2
... True/Flex Upper Extremity Intramedullary Rod System offers ... to conventional methods of rodding and plating. ... at the fracture site and enhanced healing4 ... to be easily inserted into the canal. ...
Interphlex Flexible Stablization Rods offer correction of Hammer Toes with a High level of Flexibility while maintaining correct toe length and shape....
The True/Fix Compression Hip Screw System offers a wide variety of plate and screw sizes available....
... Simple, cost-effective microfiltration for your transfusion ... also brings you an easy and ... of microfiltration for a variety of ... postoperative applications, autologous or homologous transfusions, ...
Medicine Products: